---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-035834"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T18:00:28.994236+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update

## Summary
- Completed enrollment in Phase 2 SEQUEL trial of CT1812 for mild-to-moderate Alzheimer's disease; topline results expected later 2023.
- Received FDA clearance for Phase 2 START study of CT1812 in early Alzheimer's disease and IND clearance for Phase 2 trial in geographic atrophy.
- Secured up to $35M equity commitment from Lincoln Park Capital and completed $6M follow-on public offering.
- Cash and cash equivalents $41.6M as of Dec 31, 2022, expected to fund operations into second half of 2024.
- Net loss for 2022 was $21.4M ($0.91 per share) compared to $11.7M ($3.13 per share) in 2021.

## SEC filing metadata
- accession: 0001104659-23-035834
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465923035834/0001104659-23-035834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465923035834/tm2310284d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-035834
- JSON: https://secwatch.observer/filing/0001104659-23-035834.json
- Plain text: https://secwatch.observer/filing/0001104659-23-035834.txt

## Key facts
- Earnings Releases
  COGNITION THERAPEUTICS INC reported the year ended December 31, 2022 results: net income $21.4 million, EPS $0.91 per basic and diluted share.
  - Period: the year ended December 31, 2022
  - Net income: $21.4 million
  - EPS: $0.91 per basic and diluted share
  - Result: reported results
  source text: For the year ended December 31, 2022, Cognition Therapeutics reported a net loss of $21.4 million, or $0.91 per basic and diluted share, compared to a net loss of $11.7 million, or $3.13 per basic and diluted share for 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465923035834/0001104659-23-035834-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.